

THE CLINICAL PROTEOMIC TUMOR ANALYSIS CONSORTIUM SCIENTIFIC SYMPOSIUM

Wednesday, October 16, 2019 8:30 a.m. - 6:00 p.m.

National Institutes of Health Building 35A, Porter Neuroscience Center, Rooms 610/620/630/640 35 Convent Drive, Bethesda, Maryland 20892

AGENDA

8:00 a.m 8:30 a.m.	Registration
8:30 a.m 8:45 a.m.	State of CPTAC (Status Report) Henry Rodriguez, Ph.D., M.B.A. National Cancer Institute, NIH
8:45 a.m 10:15 a.m.	Session I
8:45 a.m 9:15 a.m.	Deep Integrated Proteogenomic Characterization of Renal Cell Carcinoma David Clark, Ph.D. Johns Hopkins University
9:15 a.m 9:45 a.m.	Proteogenomic Characterization of Endometrial Carcinoma Emily Kawaler, M.S. New York University Langone Health
9:45 a.m 10:15 a.m.	Proteogenomic Analysis of Pediatric Brain Tumors and Adult Glioblastoma Multiforme (CPTAC partnership with the Gabriella Miller Kids First Pediatric Research Program) Brian R. Rood, M.D. Children's National Health System Li Ding, Ph.D. Washington University in St. Louis, School of Medicine
10:15 a.m. – 10:35 a.m.	Break
10:35 a.m 11:50 a.m.	Session II
10:35 a.m 11:00 a.m.	Proteogenomic Characterization of Ovarian High-Grade Serous Cancer Implicates Mitotic Kinase and Replication Stress Karin Rodland, Ph.D. Pacific Northwest National Laboratory; Oregon Health & Science University
11:00 a.m 11:25 a.m.	Integrated Glycoproteomic Characterization of Human High-Grade Serous Ovarian Cancer Hui Zhang, M.S., Ph.D. Johns Hopkins University School of Medicine
11:25 a.m 11:50 a.m.	Ovarian Cancer and Platinum Resistance for Clinical Trials Michael Birrer, M.D., Ph.D.

University of Alabama Comprehensive Cancer Center

11:50 a.m. - 1:30 p.m. Lunch (on your own) and Poster Viewing

1:30 p.m 3:10 p.m.	Session III
1:30 p.m 1:55 p.m.	Comprehensive Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities Bing Zhang, Ph.D. Baylor College of Medicine
1:55 p.m 2:20 p.m.	Comprehensive Proteogenomic Analysis of Human Lung Adenocarcinoma Michael A Gillette, M.D., Ph.D. Broad Institute
2:20 p.m 2:45 p.m.	Breast Cancer Proteogenomics for Clinical Trials Matthew J. Ellis, M.B., B.Chir., B.Sc., Ph.D., FRCP Baylor College of Medicine
2:45 p.m 3:10 p.m.	Global and Phosphoproteomic Analysis to Kinase Inhibitor Treatment in Acute Myeloid Leukemia (partnership with BEAT AML Master Clinical Trial) Elie Traer M.D., Ph.D. Oregon Health & Science University
3:10 p.m 3:40 p.m.	Break and Group Picture
3:40 p.m 3:45 p.m.	Welcome Remarks Douglas R. Lowy, M.D., Director (Acting) National Cancer Institute, NIH
3:45 p.m 6:00 p.m.	Session IV
3:45 p.m 6:00 p.m. 3:45 p.m 4:10 p.m.	Session IV Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays Amanda G. Paulovich, M.D., Ph.D. Fred Hutchinson Cancer Reserarch Center
	Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays Amanda G. Paulovich, M.D., Ph.D.
3:45 p.m 4:10 p.m.	Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays Amanda G. Paulovich, M.D., Ph.D. Fred Hutchinson Cancer Reserarch Center Towards Single Cell [Comprehensive] Proteomics Tao Liu, Ph.D.
3:45 p.m 4:10 p.m. 4:10 p.m 4:35 p.m.	Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays Amanda G. Paulovich, M.D., Ph.D. Fred Hutchinson Cancer Reserarch Center Towards Single Cell [Comprehensive] Proteomics Tao Liu, Ph.D. Pacific Northwest National Laboratory